DIHYDROERGOTAMINE MESYLATE Chemical Properties

Melting point:

232°C

refractive index 

-20 ° (C=0.25, JP Method)

storage temp. 

Store at RT

solubility 

methanol: 21 mg/mL

form 

powder

color 

white

Merck 

14,3174

Stability:

Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.

CAS DataBase Reference

6190-39-2(CAS DataBase Reference)

Safety Information

Hazard Codes 

Xn

Risk Statements 

20/21/22

Safety Statements 

36

RIDADR 

1544

WGK Germany 

3

RTECS 

KE7920000

HazardClass 

6.1(b)

PackingGroup 

III

HS Code 

2939690000

MSDS

• Language:English Provider:SigmaAldrich

DIHYDROERGOTAMINE MESYLATE Usage And Synthesis

Description

Dihydroergotamine mesylate (6190-39-2) is a full agonist at serotonin 5HT1B and 5HT1D receptors, IC50= 2 and 2.2 nM respectively1 and also at 5HT1A and 5HT1F receptors2. One of the oldest agents for treatment of migraine.3 Also acts as a potent vasoconstrictor and alpha-adrenergic antagonist.4

Chemical Properties

White to Off-White Solid

Uses

α-Androgenic blocker with selective venoconstrictor properties. Also binds to serotonin 5HT1-receptors. Antimigraine.

Uses

vasoconstrictor, antimigraine

Uses

Agonist at vascular serotonin receptors; partial agonist at alpha-adrenergic and dopamine D2 receptors

Definition

ChEBI: The methanesulfonic acid salt of dihydroergotamine, a semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine. Both the mesylate and the tartrate salts are used for the treatment of migraine and orthostatic hypotens on.

brand name

D.H.E. 45 (Valeant); Migranal (Valeant) .

Biological Activity

Partial α -adrenergic agonist. Partial D 2 dopaminergic receptor agonist. Competitive 5-HT antagonist.

storage

Room temperature

References

Lesage et al. (1998), Agnostic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines; J. Pharmacol., 123 1655 Silberstein (1997), The pharmacology of ergotamine and dihydroergotamine; Headache, 37 Suppl 1 S15 Silberstein and McCrory (2003), Ergotamine and dihydroergotamine: history, pharmacology, and efficacy; Headache, 43 144 Lipton (1997), Ergotamine tartrate and dihydroergotamine mesylate: safety profiles; Headache, 37 Suppl.1 S33

DIHYDROERGOTAMINE MESYLATE(6190-39-2)Related Product Information

• Rapamycin
• Tacrolimus
• Zafirlukast
• Sunitinib Malate
• Dihydroergotoxine mesylate
• DIHYDROERGOTAMINE
• ergotamine
• DIHYDROERGOTAMINE MESYLATE
• Dihydroergotamine Mesylate USP,BP,JP,Eur,Ph